Poolbeg Pharma PLC
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jeremy Skillington
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- The Clubhouse Holborn London GL United Kingdom EC4A 3AG
- IPO Date
- Apr 1, 2022
- Website
- poolbegpharma.com
- Similar Companies
- Business
- Poolbeg Pharma PLC (AIM: POLB), a clinical-stage biopharmaceutical company headquartered in London and founded in 2021, develops innovative medicines targeting unmet needs in infectious diseases, cancer immunotherapy and metabolic disorders. The company employs a capital-light model leveraging artificial intelligence and human challenge trial data for faster, cost-effective drug discovery and advancement. Poolbeg Pharma operates primarily in the United Kingdom with a global development focus and maintains a pipeline including POLB 001, an oral p38 MAPK inhibitor to prevent cytokine release syndrome associated with cancer immunotherapies such as CAR-T and bispecific antibodies; POLB 001 for severe influenza; an oral encapsulated GLP-1R agonist for obesity, diabetes and other metabolic conditions using a generally regarded as safe delivery system; AI-driven novel discovery programmes for influenza and respiratory syncytial virus; POLB 002, an in-licensed first-in-class broad-spectrum RNA-based intra-nasal immunotherapy for respiratory virus infections including influenza, RSV and SARS-CoV-2; and POLB 003, an intramuscular vaccine candidate for melioidosis prevention. Recent developments include securing orphan drug designation from the FDA for POLB 001 as a preventative therapy for T-cell engager bispecific antibody-induced cytokine release syndrome; positive in vivo data supporting POLB 001's efficacy against bispecific antibody-induced cytokine release syndrome; free supply of an approved bispecific antibody from a major pharmaceutical partner for the ongoing Phase 2a trial at The Christie hospital; a successful oversubscribed fundraising of £4.865 million in May 2025 extending cash runway into 2027 to fund POLB 001 Phase 2a and oral GLP-1 proof-of-concept trials; and preparations for multiple clinical milestones in 2026 across oncology and obesity programmes.
Company News
Poolbeg Pharma's Korean patent grant bolsters Cavendish's ‘buy' case
Poolbeg secures South Korean cancer immunotherapy-induced CRS patent
Poolbeg Pharma retains ‘buy' rating at Cavendish after safety review allows trial to continue
Poolbeg Pharma funded to finish both trials as it courts partners for cancer drug
Poolbeg Pharma doses eight patients in cancer side-effect trial
Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call Transcript
Poolbeg Pharma trial progress strengthens Cavendish case for 19p target
Poolbeg Pharma gets green light to continue clinical trial
Poolbeg wins Israeli patent nod for lead cancer immunotherapy drug
Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress
Cavendish sees multi-billion-dollar prize as Poolbeg begins pivotal trial
Poolbeg doses first patient in cancer immunotherapy safety trial
Poolbeg Pharma secures South African patent for lead drug candidate
Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish
European patent boosts Poolbeg Pharma's POLB 001 IP portfolio
Poolbeg Pharma has begun an exciting new clinical trial - ICYMI
Poolbeg Pharma shows clinical progress with latest updates
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Poolbeg Pharma gets positive FDA feedback for development pathway of lead cancer therapy asset